siRNA News and Research

RSS

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.

Researchers outline targeted therapeutic strategy for triple-negative breast cancer

New findings put forth by the University of Maryland Fischell Department of Bioengineering and researchers from four other academic institutions outline a targeted therapeutic strategy to treat triple-negative breast cancer - a potential first for the particularly aggressive form of breast cancer.

26 Feb 2019

A new treatment for Chlamydia via Canadian researchers

A new way to prevent and treat one of the commonest sexually transmitted infections (STIs) has been developed by the researchers at the University of Manitoba and the University of Waterloo. This new method is more of a gene therapy than antibiotic therapy against the infection.

6 Feb 2019

Researchers develop new way to prevent and treat Chlamydia

Researchers at the University of Waterloo have developed a new way to prevent and treat Chlamydia, the most common sexually transmitted bacterial infection in the world.

6 Feb 2019

Lab model reveals the formation of new blood vessels

To provide sufficient oxygen to tissues and organs within the body, blood vessels need to sprout new offshoots to form a widespread blood supply network, much like the trunk, branches, and twigs of a tree.

31 Jan 2019

From Our Bench to Yours: Antibody Advice from Proteintech

An interview with Dr. Karolina Szczesna, discussing the tell-tale signs of a good antibody and how Proteintech are working to improve experimental results for scientists.

From Proteintech Group, Inc 5 Dec 2018

RNAi therapy shown to alleviate preeclampsia in animal model

Researcher have used a small interfering RNA (siRNA) to reduce preeclampsia symptoms in an animal model. The approach could provide a new way of treating preeclampsia in humans.

19 Nov 2018

Combination therapy enhances wound healing

By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut healing time by half and significantly improved healing outcomes compared to control treatments.

25 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Antioxidant in green tea helps sneak therapeutic RNAs into cells

Drinking green tea has been linked to health benefits ranging from cardiovascular disease prevention to weight loss.

19 Sep 2018

Researchers describe novel mechanism that links epigenetic change to translational control

Understanding how memories form and are retrieved has applications to psychiatric, neurological and neurodegenerative disorders, and may be helpful to attenuate maladaptive memories in psychiatric disorders.

7 Sep 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

Researchers describe link between poor oocyte development and oxidative stress in obese mice

Excessive body fat is associated with negative effects on female fertility and pregnancy. In mice, maternal obesity impairs proper development of egg precursor cells called oocytes.

17 Aug 2018

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

27 Jul 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA conjugates to the central nervous system and is planning to advance a pipeline of investigational RNAi therapeutics into clinical development.

8 May 2018

Scientists discover a small family of proteins that control inclusion of DNA methylation marks in genome

Not all of your genome needs to be active at any given time. Some regions are prone to hopping around the genome in problematic ways if left unchecked; others code for genes that need to be turned off in certain cells or at certain times.